Skip to main content
Equibles
RXRX logo

RXRX · Recursion Pharmaceuticals, Inc. · Metrics

Track RXRX — free

Use RXRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RXRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.73 +0.07 (+1.93%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.96B
Shares
535.34M
Volume · Oct 21 11.75M Avg daily vol (3M) 21.64M

RXRX metrics

75 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.66
Market cap
$1.96B

Price action

20 metrics
Price change (1W)
-4.6%
Price change (30D)
-7.8%
Price change (3M)
+18.8%
Price change (6M)
+2.8%
Price change (YTD)
-10.5%
Price change (1Y)
-45.2%
Trailing year
Price change (5Y)
-80.2%
52-week high
$6.68
52-week low
$2.84
Change from 52-week high
-45.2%
Change from 52-week low
+28.9%
Annualized volatility
73.9%
Annualized volatility (3M)
91.9%
Beta
3.0
RSI (14D)
47.1
Price vs SMA 50
+0.5%
Price vs SMA 200
+2.9%
Avg volume (3M)
21.64M
Relative volume
1.0
Average dollar volume
$80.16M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
535.34M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
25.5×
reciprocal yield 3.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
35.2×
reciprocal yield 2.8%
P / book
2.1
reciprocal yield 47.3%
FCF yield
-18.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-26.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
3.5%
Operating margin
-991.7%
Trailing 12 months
Net margin
-945.9%
Gross profit (TTM)
$1.91M
Operating profit (TTM)
−$544.01M
Net income (TTM)
−$518.88M
Trailing 12 months
Diluted EPS (TTM)
$-1.00
FCF margin
-642.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.93

Growth

11 metrics
Revenue growth YoY
-60.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$54.85M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+27.6%
Year over year · more shares
Revenue CAGR (3Y)
+23.3%
Revenue CAGR (5Y)
+79.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-56.7%
Return on assets
-42.8%
Debt / equity
0.0
Current ratio
5.0
EBITDA (TTM)
−$465.65M
Free cash flow (TTM)
−$352.27M
Quick ratio
5.0
Interest coverage
-367.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$531.49M
Latest balance sheet
Cash & equivalents
$545.68M
Total assets
$1.21B
Total debt
$14.20M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$350.48M
Capital expenditures (TTM)
$1.79M
R&D (TTM)
$394.51M
SG&A (TTM)
—
Stock compensation (TTM)
$90.72M
R&D / revenue
719.2%
Stock compensation / revenue
165.4%

Ownership (13F)

9 metrics
13F filers
350
13F filer change QoQ
+10
Institutional ownership
69.3%
Conviction holders (share of 13F filers)
0.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+3.7%
Holder tenure
13.6
Price vs estimated holder cost
-57.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
21.5%

Short interest

3 metrics
Short interest
29.5%
Latest settlement · 6.1 days to cover
Days to cover
6.1d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$643,522
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1601830 CUSIP 75629V104 13F (30d) 39 filings 39 filers Visit website Investor relations